Rollover study for patients who took povorcitinib before
Treatments studied
Part of Infections, Skin clinical trials.
This study is for people who have already taken the study drug povorcitinib in a previous trial and found it helpful. It lets you continue receiving the treatment and allows doctors to keep tracking its long-term safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished treatment in a previous Incyte-sponsored study of povorcitinib without major safety issues.
- You must have had a good response to povorcitinib in that earlier study, as decided by your doctor.
- You must be willing to follow the study rules and avoid pregnancy or fathering children as outlined in the protocol.
- You cannot have been permanently stopped from taking the study drug in the earlier trial.
- You cannot have taken certain other immune-modulating drugs or live vaccines within 28 days before starting this study, or plan to take a live vaccine during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
This study offers long-term treatment with an investigational biologic, sonelokimab, for people with moderate to severe hidradenitis suppurativa who finished an earlier sonelokimab study. The goal is to see if sonelokimab remains safe and effective over time.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.